The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).
David R. Spigel
Consultant or Advisory Role - Clovis (U)
Roberta Cereda
Employment or Leadership Position - EOS S.p.A.
Jason B. Litten
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Giuseppe Giaccone
Consultant or Advisory Role - Clovis (U)
Mark A. Socinski
No relevant relationships to disclose
D. Ross Camidge
Consultant or Advisory Role - Clovis
Benjamin Besse
No relevant relationships to disclose